EGFR and neoplasm: EGFR inhibitors block ligand-binding, abrogating activation of downstream tumor-promoting pathways including apoptosis evasion (PI3K-Akt), proliferation (Ras-Raf-MEK-MAPK), and transcription (STAT3)8.